ABI
EW icon

Adamant Biomedical Investments’s Edwards Lifesciences EW Stock Holding History

Adamant Biomedical Investments’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$1.85M Hold
87,000
– – 0.44% 68
2014
Q3 		$1.48M Buy
+87,000
New +$1.37M 0.37% 71

Other funds holding EW

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Adamant Biomedical Investments's EW Position: Q4 2014 in Review

Adamant Biomedical Investments held its Edwards Lifesciences (EW) position steady in Q4 2014 at 87,000 shares worth $1.85M. The position accounts for 0.44% of the portfolio, ranked #68.

Adamant Biomedical Investments first reported a position in EW in Q3 2014 and has held it in 2 quarters since. 556 funds tracked by Wall St. Rank hold EW as of Q4 2014.

  • Adamant Biomedical Investments held 87,000 shares of Edwards Lifesciences worth $1.85M as of Q4 2014.
  • Adamant Biomedical Investments left its Edwards Lifesciences share count unchanged in Q4 2014.
  • Edwards Lifesciences made up 0.44% of Adamant Biomedical Investments's portfolio in Q4 2014, its #68 holding.
  • Adamant Biomedical Investments first reported a position in Edwards Lifesciences in Q3 2014 and has held it in 2 quarters since.
  • 556 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.